NACSELD acute‐on‐chronic liver failure (NACSELD‐ACLF) score predicts 30‐day survival in hospitalized patients with cirrhosis

Jacqueline G. O’Leary(Baylor University Medical Center), Jasmohan S. Bajaj(Virginia Commonwealth University), Scott W. Biggins(University of Colorado Denver), Guadalupe García–Tsao(Yale University), Hugo E. Vargas(Mayo Clinic in Arizona), Puneeta Tandon(University of Alberta), K. Rajender Reddy(University of Pennsylvania Health System), Benedict Maliakkal(University of Rochester Medical Center), Michael B. Fallon(University of Arizona), Paul J. Thuluvath(Inova Fairfax Hospital), Florence Wong(University of Toronto), Jennifer C. Lai(University of California, San Francisco), Patrick S. Kamath(Mayo Clinic), Ram Subramanian(Emory University), Leroy R. Thacker(Virginia Commonwealth University)
Hepatology
January 10, 2018
10.1002/hep.29773
Cited by 270

Related Papers

Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
|Hepatology|2014|2k
Global burden of liver disease: 2023 update
|Journal of Hepatology|2023|1.9k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List
|New England Journal of Medicine|2008|1.5k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k